Skip to main content
. 2022 Jun 6;10(16):5446–5455. doi: 10.12998/wjcc.v10.i16.5446

Table 1.

Motivational interviewing case management genotyping of the cases

Number
Age
Sex
FABtyping
Karyotype
Immunological phenotype
Genemutation
Therapeutic reaction
Prognosis
Ref.
1 27 F M3 i(17)(q10) CD33+/CD13+/ MPO PML-RARa (-) Retinoic acid (-) Die (survival 1 mo) Yan et al[15], China
2 10 M M3 i(17)(q10) - - NR Die (survival < 1 mo) Bernstein et al[14], South Africa
3 Child F - i(17)(q10) - - - - Raimondi et al[13], Mexico
4 - - M3 i(17)(q10) - - - - Becher et al[19]
5 3 (Case 1) M M3 i(17)(q10) CD9/CD13/CD33/ CD38/CD64/CD123/CD58/MPO WT1/EP300/C.854delG: P w285fs Frame shiftC.C2102T: P.701LMissense - Wen JQ, China
6 12 (Case 2) M M3 i(17)(q10) Add(14) (p11) CD9/CD13/CD33/ CD38/CD64/CD123/CD15/MPO WT1/TAL1/TTN/DDX11 + CR 36 months, WT1 copy: 1010-1087 Wen JQ, China

F: Female; M: Male.